Pharmacological manipulation of the Akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells

Journal of Virology

Volumn 84, Issue 7, 2010, Pages 3287-3302

  Werden, Steven J ^a   McFadden, Grant ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; OKADAIC ACID; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN M T5; RAPAMYCIN; THREONINE; TRICIRIBINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MYXOMA VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; VIRUS REPLICATION;

CELL LINE, TUMOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MYXOMA VIRUS; NEOPLASMS; OKADAIC ACID; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROPYLENE GLYCOLS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; SPHINGOSINE; VIRAL PROTEINS; VIRAL TROPISM; VIRUS REPLICATION;

MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS; POXVIRIDAE;

EID: 77949414467     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02020-09     Document Type: Article

References (64)

1. Ahn, J. Y., R. Rong, T. G. Kroll, E. G. Van Meir, S. H. Snyder, and K. Ye. 2004. PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J. Biol. Chem. 279:16441-16451.
2. Alessi, D. R., M. Andjelkovic, B. Caudwell, P. Cron, N. Morrice, P. Cohen, and B. A. Hemmings. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15:6541-6551.
3. Azuma, H., S. Takahara, S. Horie, S. Muto, Y. Otsuki, and Y. Katsuoka. 2003. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol. 169:2372-2377.
4. Azuma, H., S. Takahara, N. Ichimaru, J. D. Wang, Y. Itoh, Y. Otsuki, J. Morimoto, R. Fukui, M. Hoshiga, T. Ishihara, N. Nonomura, S. Suzuki, A. Okuyama, and Y. Katsuoka. 2002. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 62:1410-1419.
5. Barnett, S. F., D. Defeo-Jones, S. Fu, P. J. Hancock, K. M. Haskell, R. E. Jones, J. A. Kahana, A. M. Kral, K. Leander, L. L. Lee, J. Malinowski, E. M. McAvoy, D. D. Nahas, R. G. Robinson, and H. E. Huber. 2005. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385:399-408.
6. Barrett, J. W., L. R. Alston, F. Wang, M. M. Stanford, P. A. Gilbert, X. Gao, J. Jimenez, D. Villeneuve, P. Forsyth, and G. McFadden. 2007. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J. Neurovirol. 13:549-560.
7. Bellacosa, A., J. R. Testa, S. P. Staal, and P. N. Tsichlis. 1991. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254:274-277.
8. Brinkmann, V., J. G. Cyster, and T. Hla. 2004. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4:1019-1025.
9. Buchkovich, N. J., Y. Yu, C. A. Zampieri, and J. C. Alwine. 2008. The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway. Nat. Rev. Microbiol. 6:266-275.
10. Chiba, K., Y. Hoshino, C. Suzuki, Y. Masubuchi, Y. Yanagawa, M. Ohtsuki, S. Sasaki, and T. Fujita. 1996. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant. Proc. 28:1056-1059.
11. Cooray, S. 2004. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J. Gen. Virol. 85:1065-1076.
12. DeFeo-Jones, D., S. F. Barnett, S. Fu, P. J. Hancock, K. M. Haskell, K. R. Leander, E. McAvoy, R. G. Robinson, M. E. Duggan, C. W. Lindsley, Z. Zhao, H. E. Huber, and R. E. Jones. 2005. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. 4:271-279.
13. Engelman, J. A. 2009. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9:550-562.
14. Fenner, F. 2000. Adventures with poxviruses of vertebrates. FEMS Microbiol. Rev. 24:123-133.
15. Fenner, F. 1983. The Florey lecture, 1983. Biological control, as exemplified by smallpox eradication and myxomatosis. Proc. R. Soc. Lond. B Biol. Sci. 218:259-285.
16. Gingras, A. C., B. Raught, and N. Sonenberg. 2004. mTOR signaling to translation. Curr. Top. Microbiol. Immunol. 279:169-197.
17. Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-189.
18. Hu, Y., L. Qiao, S. Wang, S. B. Rong, E. J. Meuillet, M. Berggren, A. Gallegos, G. Powis, and A. P. Kozikowski. 2000. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J. Med. Chem. 43:3045-3051.
19. Johnston, J. B., G. Wang, J. W. Barrett, S. H. Nazarian, K. Colwill, M. Moran, and G. McFadden. 2005. Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1. J. Virol. 79:10750-10763.
20. Jones, P. F., T. Jakubowicz, F. J. Pitossi, F. Maurer, and B. A. Hemmings. 1991. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc. Natl. Acad. Sci. U. S. A. 88:4171-4175.
21. Karst, A. M., D. L. Dai, J. Q. Cheng, and G. Li. 2006. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res. 66:9221-9226.
22. Lee, T. K., K. Man, J. W. Ho, C. K. Sun, K. T. Ng, X. H. Wang, Y. C. Wong, I. O. Ng, R. Xu, and S. T. Fan. 2004. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 25:2397-2405.
23. Lindsley, C. W., Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett, D. Defeo-Jones, R. E. Jones, G. D. Hartman, J. R. Huff, H. E. Huber, and M. E. Duggan. 2005. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15:761-764.
24. Lun, X., W. Yang, T. Alain, Z. Q. Shi, H. Muzik, J. W. Barrett, G. McFadden, J. Bell, M. G. Hamilton, D. L. Senger, and P. A. Forsyth. 2005. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 65:9982-9990.
25. Lun, X. Q., H. Zhou, T. Alain, B. Sun, L. Wang, J. W. Barrett, M. M. Stanford, G. McFadden, J. Bell, D. L. Senger, and P. A. Forsyth. 2007. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 67:8818-8827.
26. Matsuoka, Y., Y. Nagahara, M. Ikekita, and T. Shinomiya. 2003. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 138:1303-1312.
27. Matsuura, M., T. Imayoshi, K. Chiba, and T. Okumoto. 2000. Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm. Res. 49:404-410.
28. McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3:201-213.
29. Mercer, A. A., S. B. Fleming, and N. Ueda. 2005. F-box-like domains are present in most poxvirus ankyrin repeat proteins. Virus Genes 31:127-133.
30. Meric-Bernstam, F., and A. M. Gonzalez-Angulo. 2009. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27:2278-2287.
31. Mossman, K., S. F. Lee, M. Barry, L. Boshkov, and G. McFadden. 1996. Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. J. Virol. 70:4394-4410.
32. Nagahara, Y., M. Ikekita, and T. Shinomiya. 2000. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J. Immunol. 165:3250-3259.
33. Nagahara, Y., Y. Matsuoka, K. Saito, M. Ikekita, S. Higuchi, and T. Shinomiya. 2001. Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn. J. Cancer Res. 92:680-687.
34. Nicholson, K. M., and N. G. Anderson. 2002. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 14:381-395.
35. Opgenorth, A., K. Graham, N. Nation, D. Strayer, and G. McFadden. 1992. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J. Virol. 66:4720-4731.
36. O'Reilly, K. E., F. Rojo, Q. B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, J. Baselga, and N. Rosen. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-1508.
37. Oshiro, N., K. Yoshino, S. Hidayat, C. Tokunaga, K. Hara, S. Eguchi, J. Avruch, and K. Yonezawa. 2004. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9:359-366.
38. Plas, D. R., and G. Thomas. 2009. Tubers and tumors: rapamycin therapy for benign and malignant tumors. Curr. Opin. Cell Biol. 21:230-236.
39. Ramaswamy, S., N. Nakamura, F. Vazquez, D. B. Batt, S. Perera, T. M. Roberts, and W. R. Sellers. 1999. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. U. S. A. 96:2110-2115.
40. Sarbassov, D. D., S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, and D. M. Sabatini. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22:159-168.
41. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
42. Seet, B. T., J. B. Johnston, C. R. Brunetti, J. W. Barrett, H. Everett, C. Cameron, J. Sypula, S. H. Nazarian, A. Lucas, and G. McFadden. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
43. Shen, Y., M. Cai, W. Xia, J. Liu, Q. Zhang, H. Xie, C. Wang, X. Wang, and S. Zheng. 2007. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett. 254:288-297.
44. Shi, Y., H. Yan, P. Frost, J. Gera, and A. Lichtenstein. 2005. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4:1533-1540.
45. Soares, J. A., F. G. Leite, L. G. Andrade, A. A. Torres, L. P. De Souza, L. S. Barcelos, M. M. Teixeira, P. C. Ferreira, E. G. Kroon, T. Souto-Padron, and C. A. Bonjardim. 2009. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infectionis required for both host survival and viral replication. J. Virol. 83:6883-6899.
46. Staal, S. P., J. W. Hartley, and W. P. Rowe. 1977. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc. Natl. Acad. Sci. U. S. A. 74:3065-3067.
47. Stanford, M. M., J. W. Barrett, S. H. Nazarian, S. Werden, and G. McFadden. 2007. Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J. Virol. 81:1251-1260.
48. Stanford, M. M., S. J. Werden, and G. McFadden. 2007. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet. Res. 38:299-318.
49. Stephens, L., K. Anderson, D. Stokoe, H. Erdjument-Bromage, G. F. Painter, A. B. Holmes, P. R. Gaffney, C. B. Reese, F. McCormick, P. Tempst, J. Coadwell, and P. T. Hawkins. 1998. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279:710-714.
50. Stokoe, D., L. R. Stephens, T. Copeland, P. R. Gaffney, C. B. Reese, G. F. Painter, A. B. Holmes, F. McCormick, and P. T. Hawkins. 1997. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277:567-570.
51. Suzuki, K., T. Kazui, A. Kawabe, X. K. Li, N. Funeshima, H. Amemiya, and S. Suzuki. 1998. Immunosuppressive effect of FTY 720 on rat pancreas allograft. Transplant. Proc. 30:3417-3418.
52. Suzuki, S., S. Enosawa, T. Kakefuda, H. Amemiya, Y. Hoshino, and K. Chiba. 1996. Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720. Transplant. Proc. 28: 1375-1376.
53. Suzuki, S., S. Enosawa, T. Kakefuda, T. Shinomiya, M. Amari, S. Naoe, Y. Hoshino, and K. Chiba. 1996. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 61:200-205.
54. Sypula, J., F. Wang, Y. Ma, J. Bell, and G. McFadden. 2004. Myxoma virus tropism in human tumour cells. Gene Ther. Mol. Biol. 8:103-114.
55. Testa, J. R., and A. Bellacosa. 2001. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98:10983-10985.
56. Thimmaiah, K. N., J. B. Easton, G. S. Germain, C. L. Morton, S. Kamath, J. K. Buolamwini, and P. J. Houghton. 2005. Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J. Biol. Chem. 280:31924-31935.
57. Wang, G., J. W. Barrett, M. Stanford, S. J. Werden, J. B. Johnston, X. Gao, M. Sun, J. Q. Cheng, and G. McFadden. 2006. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. U. S. A. 103:4640-4645.
58. Wang, J. D., S. Takahara, N. Nonomura, N. Ichimaru, K. Toki, H. Azuma, K. Matsumiya, A. Okuyama, and S. Suzuki. 1999. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 40:50-55.
59. Werden, S. J., J. W. Barrett, G. Wang, M. M. Stanford, and G. McFadden. 2007. M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J. Virol. 81:2340-2348.
60. Woo, Y., K. J. Kelly, M. M. Stanford, C. Galanis, Y. S. Chun, Y. Fong, and G. McFadden. 2008. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann. Surg. Oncol. 15:2329-2335.
61. Wu, Y., X. Lun, H. Zhou, L. Wang, B. Sun, J. C. Bell, J. W. Barrett, G. McFadden, J. A. Biegel, D. L. Senger, and P. A. Forsyth. 2008. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin. Cancer Res. 14:1218-1227.
62. Yang, L., H. C. Dan, M. Sun, Q. Liu, X. M. Sun, R. I. Feldman, A. D. Hamilton, M. Polokoff, S. V. Nicosia, M. Herlyn, S. M. Sebti, and J. Q. Cheng. 2004. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64:4394-4399.
63. Zeng, Z., D. D. Sarbassov, I. J. Samudio, K. W. Yee, M. F. Munsell, C. E. Jackson, F. J. Giles, D. M. Sabatini, M. Andreeff, and M. Konopleva. 2007. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109:3509-3512.
64. Zhao, Z., W. H. Leister, R. G. Robinson, S. F. Barnett, D. Defeo-Jones, R. E. Jones, G. D. Hartman, J. R. Huff, H. E. Huber, M. E. Duggan, and C. W. Lindsley. 2005. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett. 15:905-909.